ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

On May 27, 2020 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that multiple poster presentations highlighting preclinical data from the company’s glucocorticoid receptor (GR) antagonist and CD73 inhibitor programs will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II being held June 22-24, 2020 (Press release, ORIC Pharmaceuticals, MAY 27, 2020, View Source [SID1234561056]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the planned presentations are as follows:

ORIC-101 (GR Antagonist) Poster Presentations:
Title: ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models
Date: June 22, 2020
Session: Mechanisms of Sensitivity and Resistance to Targeting Hormone Responsive Cancer
Abstract: 4120

Title: ORIC-101 overcomes resistance to diverse chemotherapeutics across cancer types
Date: June 22, 2020
Session: Mechanisms of Sensitivity and Resistance to Targeting Hormone Responsive Cancer
Abstract: 4121

Title: ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models
Date: June 22, 2020
Session: Mechanisms of Sensitivity and Resistance to Targeting Hormone Responsive Cancer
Abstract: 4123

ORIC-533 (CD73 Inhibitor) Poster Presentations:
Title: CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cells activation
Date: June 22, 2020
Session: Tumor Induced Immune Suppression
Abstract: 1023

Title: An orally bioavailable inhibitor of CD73 reverts intratumoral immunosuppression and promotes anti-tumor responses
Date: June 22, 2020
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Abstract: LB-115